2025-05-22 06:01:36 pm | Source: reuters
India`s Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
Sun Pharmaceutical, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Buy Welspun Living Ltd For Target Rs.260 by Motilal ...
Sell Deepak Nitrite Ltd For Target Rs.1,300 by Motil...
Buy MTAR Technologies Ltd For Target Rs.9,000 by Mot...
Buy Motherson Wiring Ltd For Target Rs.45 by Motila...
Neutral Navin Fluorine International Ltd For Target ...
Groww opens US stock investing to all: 5 things to know
Buy Dixon Technologies Ltd For Target Rs.15,900 by M...
Tamil Nadu government makes GPS mandatory for minera...
Quad unveils AI, minerals and maritime plans
Centre releases additional tax devolution instalment...
